Finance

Lists
LSTA:NASDAQ
Lisata Therapeutics Inc
$1.09
-3.54%
(-0.040) 1D
Aug 14, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LSTA...
Open
$1.10
High
$1.15
Low
$1.05
Mkt. cap
9.82M
Avg. vol.
103.78K
Volume
0.00
52-wk high
$5.07
52-wk low
$0.99
EPS
-$1.64
Beta
0.88
Shares outstanding
9.01M
No. of employees
21
Open
$1.10
High
$1.15
Low
$1.05
Mkt. cap
9.82M
Avg. vol.
103.78K
Volume
0.00
52-wk high
$5.07
52-wk low
$0.99
EPS
-$1.64
Beta
0.88
Shares outstanding
9.01M
No. of employees
21
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics Inc
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, New Jersey, United States
SectorBiotechnology
Websitelisata.com
Analyst ratings
Based on 2 analysts giving stock ratings to LSTA in the past 3 months
Hold
Buy
0
Hold
2
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for LSTA in the last 3 months.
Highest
Current $1.09
(-100.00%)
Average
(-100.00%)
Lowest
(-100.00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kemp Dolliver
Brookline Capital Markets
Hold
Downgraded
-
-
07/27/2026
Joseph Pantginis
H.C. Wainwright
Hold
Downgraded
-
-
05/18/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
100.00K
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.96M
1.13M
1.20M
584.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.46M
2.04M
3.74M
3.41M
Operating expense
4.41M
3.18M
4.94M
3.99M
Total operating expenses
4.41M
3.18M
4.94M
3.99M
Operating income
-4.41M
-3.08M
-4.94M
-3.99M
Other non operating income
-18.00K
-16.00K
-16.00K
984.00K
EBT including unusual items
-4.25M
-2.95M
-4.88M
-2.93M
EBT excluding unusual items
-4.25M
-2.95M
-4.84M
-2.93M
Income tax expense
-
-
-387.00K
-
Effective tax rate
-
-
7.94%
-
Other operating expenses
-
-
-
-
Net income
-4.25M
-2.95M
-4.49M
-2.93M
Net profit margin
-
-2,954.00%
-
-
Earnings per share
-0.49
-
-
-
Interest and investment income
183.00K
141.00K
120.00K
79.00K
Interest expense
-
-
-
-
Net interest expenses
183.00K
141.00K
120.00K
79.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.37M
-3.06M
-4.94M
-3.99M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps